65,437 trials
Chronic Hepatitis C
Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing — 46.3; 69.1; 59.8…
Hepatitis C
Primary: Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After…
Labor Pain · Pregnancy
Primary: Number of Parturients With a Decrease in the Infusion of Epidural Analgesia During Second Stage of Labor — 146; 51 participants — p=<0.01
Low Back Pain
Primary: Cost Per Successful Procedure — 15,241; 17,142; 6286 U.S. dollars
Hepatitis C
Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing — 51.3; 53.1; 24.3…
Hemophilia A
Primary: Area Under the Curve — 1257.20; 1297.42 IU*h/dL
Preterm Birth
Primary: Rate of Recurrent Preterm Birth — 5; 8 participants
Metrorrhagia
Primary: Mean Number of Bleeding or Spotting Days — 16; 28 days
Chronic Hepatitis C
Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing — 41.3; 67.1; 60.8…
Hepatitis C
Primary: Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment…
Chronic Kidney Disease · Chronic Renal Disease
Primary: Delivered Single-pool Kt/Vurea (spKt/V) at Dialysate Flow Rates of 600 mL/Min and 800 mL/Min. — 1.66; 1.63 single-pool Kt/Vurea (spKt/V)
Hemorrhoids · Pain
Primary: NRS Pain = Numeric Rating Scale (0-10) — 1.6; 1.5 Units on a scale — p=>0.05
Diabetes Mellitus Type 2
Primary: Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study — -12.595; -29.518; -30.429; -32.586 mg/dL — p=0.0989
Hepatitis
Primary: Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category) — 9; 11; 5; 1 participants — p=<0.001
Genital Warts
Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants